Lytix Biopharma AS (OSL:LYTIX) Change In Receivables : kr-8.65 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lytix Biopharma AS Change In Receivables?

Lytix Biopharma AS's change in receivables for the quarter that ended in Sep. 2024 was kr4.51 Mil. It means Lytix Biopharma AS's Accounts Receivable declined by kr4.51 Mil from Jun. 2024 to Sep. 2024 .

Lytix Biopharma AS's change in receivables for the fiscal year that ended in Dec. 2023 was kr-6.04 Mil. It means Lytix Biopharma AS's Accounts Receivable increased by kr6.04 Mil from Dec. 2022 to Dec. 2023 .

Lytix Biopharma AS's Accounts Receivable for the quarter that ended in Sep. 2024 was kr9.90 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Lytix Biopharma AS's Days Sales Outstanding for the three months ended in Sep. 2024 was 3,911.50.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Lytix Biopharma AS's liquidation value for the three months ended in Sep. 2024 was kr31.50 Mil.

Lytix Biopharma AS Change In Receivables Historical Data

The historical data trend for Lytix Biopharma AS's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lytix Biopharma AS Change In Receivables Chart

Lytix Biopharma AS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

4.64

0.47

-1.51

-1.06

-6.04

Lytix Biopharma AS Quarterly Data
	Dec18	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															4.71	-11.53	-6.06	4.43	4.51

Lytix Biopharma AS Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-8.65 Mil.

Lytix Biopharma AS (OSL:LYTIX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Lytix Biopharma AS's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	9.902	/	0.231	*	91
=	3,911.50

2. In Ben Graham's calculation of liquidation value, Lytix Biopharma AS's accounts receivable are only considered to be worth 75% of book value:

Lytix Biopharma AS's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	43.529	-	19.453	+	0.75 * 9.902	+	0.5 * 0
=	31.50

Lytix Biopharma AS Change In Receivables Related Terms

Thank you for viewing the detailed overview of Lytix Biopharma AS's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Lytix Biopharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lytix Biopharma AS (OSL:LYTIX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

6BG:Germany

Address

Sandakerveien 138, Oslo, NOR, 0484

Website

https://www.lytixbiopharma.com

Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401, and LTX-315 are in the pipeline.

Lytix Biopharma AS Headlines

No Headlines